Bluebird Bio Net Worth
Bluebird Bio Net Worth Breakdown | BLUE |
Bluebird Bio Net Worth Analysis
Bluebird Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bluebird Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bluebird Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bluebird Bio's net worth analysis. One common approach is to calculate Bluebird Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bluebird Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bluebird Bio's net worth. This approach calculates the present value of Bluebird Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bluebird Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bluebird Bio's net worth. This involves comparing Bluebird Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bluebird Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Bluebird Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bluebird Bio's net worth research are outlined below:
| Bluebird bio generated a negative expected return over the last 90 days | |
| Bluebird bio has high historical volatility and very poor performance | |
| Bluebird bio has some characteristics of a very speculative penny stock | |
| Bluebird bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.5 M. Net Loss for the year was (211.91 M) with loss before overhead, payroll, taxes, and interest of (247.24 M). | |
| Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bluebird bio has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: BLUE LOCK CEMENTS ITSELF AS AN INTERNATIONAL HIT AS EPISODE NAGI EARNS 23.3 MILLION AT THE GLOBAL BOX OFFICE |
Bluebird Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bluebird bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bluebird Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bluebird Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bluebird Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bluebird bio backward and forwards among themselves. Bluebird Bio's institutional investor refers to the entity that pools money to purchase Bluebird Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-06-30 | 1.2 M | Jane Street Group Llc | 2024-06-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1.1 M | Masters Capital Management Llc | 2024-09-30 | 975 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 968.9 K | Goldman Sachs Group Inc | 2024-09-30 | 805.2 K | Two Sigma Advisers, Llc | 2024-09-30 | 713.1 K | Aqr Capital Management Llc | 2024-09-30 | 678.2 K | Jpmorgan Chase & Co | 2024-09-30 | 621.9 K | Blackrock Inc | 2024-06-30 | 15.4 M | Vanguard Group Inc | 2024-09-30 | 10.5 M |
Follow Bluebird Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 69.71 M.Market Cap |
|
Project Bluebird Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.09) | (1.03) |
When accessing Bluebird Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bluebird Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bluebird Bio's profitability and make more informed investment decisions.
Please note, the presentation of Bluebird Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bluebird Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bluebird Bio's management manipulating its earnings.
Evaluate Bluebird Bio's management efficiency
Bluebird bio has return on total asset (ROA) of (0.3624) % which means that it has lost $0.3624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.867) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio's management efficiency ratios could be used to measure how well Bluebird Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Bluebird Bio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 10.8 M, whereas Other Assets are forecasted to decline to about 33.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.77 | 1.68 | |
| Tangible Book Value Per Share | 1.62 | 1.54 | |
| Enterprise Value Over EBITDA | (1.56) | (1.63) | |
| Price Book Value Ratio | 0.78 | 0.46 | |
| Enterprise Value Multiple | (1.56) | (1.63) | |
| Price Fair Value | 0.78 | 0.46 | |
| Enterprise Value | 380.2 M | 386.4 M |
Bluebird bio benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Enterprise Value Revenue 7.132 | Revenue 54.9 M | Quarterly Revenue Growth 1.337 | Revenue Per Share 0.357 | Return On Equity (1.87) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluebird Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluebird Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bluebird Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Colvin Richard A over three months ago Disposition of 2343 shares by Colvin Richard A of Bluebird Bio at 2.9769 subject to Rule 16b-3 | ||
Sterling O. James over three months ago Acquisition by Sterling O. James of 300000 shares of Bluebird Bio at 0.98 subject to Rule 16b-3 | ||
Cloonan Michael over three months ago Insider Trading | ||
Jeffrey Walsh over six months ago Sale by Jeffrey Walsh of 300 shares of Bluebird Bio | ||
Jeffrey Walsh over six months ago Exercise or conversion by Jeffrey Walsh of 100 shares of Bluebird Bio subject to Rule 16b-3 | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 200 shares of Bluebird Bio | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 100 shares of Bluebird Bio |
Bluebird Bio Earnings per Share Projection vs Actual
Bluebird Bio Corporate Management
| Mr MD | Chief Officer | Profile | |
| Melissa Bonner | VP Research | Profile | |
| Andrea Walton | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Christopher CPA | Principal CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.